(Q44343973)

2 December 2017

title

Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment (English)

1 reference

2 December 2017

0 references

C Kluft

1

1 reference

2 December 2017

J A Gevers Leuven

series ordinal

2

1 reference

2 December 2017

F M Helmerhorst

series ordinal

3

1 reference

2 December 2017

H M J Krans

series ordinal

4

1 reference

2 December 2017

publication date

1 August 2002

1 reference

2 December 2017

published in

Vascular Pharmacology

1 reference

2 December 2017

volume

39

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

149-154

1 reference

2 December 2017

cites work

The acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Effect of 17 beta-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Oral contraceptives, fibrinogen and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein.

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Serum neopterin in acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Enhanced Inflammatory Response to Coronary Angioplasty in Patients With Severe Unstable Angina

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Hormone replacement therapy and risk of venous thromboembolism: population based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Hormone replacement therapy and heart disease prevention: experimentation trumps observation

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Room temperature, microtray chromogenic assay of factor VIII:C.

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Hormone replacement therapy and increased plasma concentration of C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor

1 reference

https://api.crossref.org/works/10.1016%2FS1537-1891%2802%2900304-X

7 January 2021

10.1016/S1537-1891(02)00304-X

Identifiers

DOI

1 reference

2 December 2017

1 reference